The discovery could help explain why some cancer patients respond well to certain treatments, while others are not so lucky.

Fighting cancer can seem like a deadly game of chance. While some patients may respond well to certain treatments, others might not be as fortunate.

Fighting cancer can seem like a deadly game of chance. While some patients may respond well to certain treatments, others might not be as fortunate.

MUSC Hollings Cancer Center researcher Aguirre de Cubas, Ph.D., is a recipient of the Department of Defense Academy of Kidney ...

EEDVD-682 is under clinical development by EnGeneIC and currently in Phase II for Kidney Cancer (Renal Cell Cancer).

PHILADELPHIA- Fighting cancer can seem like a deadly game of chance. While some patients may respond well to certain ...

A biologics license application for TLX250-CDx has been submitted to the FDA, as supported by the phase 3 ZIRCON trial ...

Fighting cancer can seem like a deadly game of chance. While some patients may respond well to certain treatments, others might not be as fortunate. Doctors and scientists have long struggled to ...

Fighting cancer can seem like a deadly game of chance. While some patients may respond well to certain treatments, others might not be as fortunate. Doctors and scientists have long struggled to ...

Fighting cancer can seem like a deadly game of chance. While some patients may respond well to certain treatments, others ...

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Kidney Cancer (Renal Cell Cancer).